NASDAQ:UBX Unity Biotechnology (UBX) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free UBX Stock Alerts $1.61 -0.02 (-1.23%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$1.59▼$1.6350-Day Range$1.47▼$1.8752-Week Range$1.46▼$3.82Volume30,754 shsAverage Volume81,798 shsMarket Capitalization$27.03 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Unity Biotechnology alerts: Email Address Unity Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside272.7% Upside$6.00 Price TargetShort InterestHealthy1.99% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.96) to ($2.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector1447th out of 5,430 stocksPharmaceutical Preparations Industry619th out of 2,526 stocks 3.5 Analyst's Opinion Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUnity Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.99% of the float of Unity Biotechnology has been sold short.Short Interest Ratio / Days to CoverUnity Biotechnology has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Unity Biotechnology has recently decreased by 0.78%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldUnity Biotechnology does not currently pay a dividend.Dividend GrowthUnity Biotechnology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnity Biotechnology has received a 74.69% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Unity Biotechnology is -0.60. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unity Biotechnology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Unity Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 29.49% of the stock of Unity Biotechnology is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Unity Biotechnology are expected to decrease in the coming year, from ($1.96) to ($2.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unity Biotechnology is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unity Biotechnology is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUnity Biotechnology has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Unity Biotechnology Stock (NASDAQ:UBX)Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.Read More UBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UBX Stock News HeadlinesApril 25, 2024 | globenewswire.comUNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual MeetingApril 23, 2024 | globenewswire.comUNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DMEMay 3, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 15, 2024 | investorplace.comUBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023April 15, 2024 | globenewswire.comUNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesApril 9, 2024 | finance.yahoo.comUnity Biotechnology, Inc. (0YC0.L)February 17, 2024 | finance.yahoo.comUBX Mar 2024 2.000 callFebruary 7, 2024 | uk.investing.comUnity Biotechnology Inc (UBX)May 3, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.February 6, 2024 | finance.yahoo.comNew Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision LossDecember 29, 2023 | finance.yahoo.com10 Supplements for Longevity and Antiaging: Expert RecommendationsDecember 12, 2023 | finance.yahoo.comUNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DMENovember 27, 2023 | msn.comUnity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63November 17, 2023 | msn.comWedbush Upgrades Unity Biotechnology (UBX)November 16, 2023 | msn.comWedbush upgrades Unity Biotechnology to outperform, cites cash runwayNovember 16, 2023 | finance.yahoo.comCompanies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite RiskyNovember 15, 2023 | markets.businessinsider.comUnity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy RatingNovember 14, 2023 | finanznachrichten.deUnity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 14, 2023 | msn.comUnity Biotechnology GAAP EPS of -$1.05 misses by $0.16November 13, 2023 | tmcnet.comUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 13, 2023 | finance.yahoo.comUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 10, 2023 | msn.comUNITY Biotechnology to exercise warrants for $4.38M in gross proceedsNovember 10, 2023 | finance.yahoo.comUNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross ProceedsOctober 25, 2023 | finance.yahoo.comAre Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging PicksOctober 3, 2023 | finance.yahoo.com20 Foods Consumed By Longest Living People Every DaySeptember 28, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Unity Biotechnology (UBX) and Rockwell Med (RMTI)September 27, 2023 | markets.businessinsider.comUNITY Biotechnology Reports Encouraging Results From Phase 2 ENVISION Study Of UBX1325See More Headlines Receive UBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today5/03/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:UBX CUSIPN/A CIK1463361 Webwww.unitybiotechnology.com Phone(650) 416-1192FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+272.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.06% Return on Assets-46.86% Debt Debt-to-Equity RatioN/A Current Ratio5.94 Quick Ratio5.94 Sales & Book Value Annual Sales$240,000.00 Price / Sales112.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book0.95Miscellaneous Outstanding Shares16,790,000Free Float15,964,000Market Cap$27.03 million OptionableOptionable Beta0.86 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Anirvan Ghosh Ph.D. (Age 60)CEO & Director Comp: $1.08MDr. Nathaniel E. David A.B. (Age 56)Ph.D., Co-Founder & Executive Director Comp: $40kMs. Lynne Marie Sullivan (Age 57)CFO & Head of Corporate Development Comp: $730.82kDr. Jan M. van DeursenFounderDr. Judith Campisi Ph.D.FounderMr. Daohong Zhou M.D.FounderMore ExecutivesKey CompetitorsAcasti PharmaNASDAQ:ACSTNRx PharmaceuticalsNASDAQ:NRXPSensei BiotherapeuticsNASDAQ:SNSEIterum TherapeuticsNASDAQ:ITRMForte BiosciencesNASDAQ:FBRXView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 688,000 shares on 2/13/2024Ownership: 4.100%Anirvan GhoshSold 1,183 sharesTotal: $2,022.93 ($1.71/share)Anirvan GhoshSold 1,024 sharesTotal: $1,945.60 ($1.90/share)Anirvan GhoshSold 1,246 sharesTotal: $3,077.62 ($2.47/share)Anirvan GhoshSold 1,177 sharesTotal: $3,766.40 ($3.20/share)View All Insider TransactionsView All Institutional Transactions UBX Stock Analysis - Frequently Asked Questions Should I buy or sell Unity Biotechnology stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UBX shares. View UBX analyst ratings or view top-rated stocks. What is Unity Biotechnology's stock price target for 2024? 2 equities research analysts have issued 1-year target prices for Unity Biotechnology's shares. Their UBX share price targets range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 272.7% from the stock's current price. View analysts price targets for UBX or view top-rated stocks among Wall Street analysts. How have UBX shares performed in 2024? Unity Biotechnology's stock was trading at $1.93 at the beginning of the year. Since then, UBX shares have decreased by 16.6% and is now trading at $1.61. View the best growth stocks for 2024 here. When is Unity Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our UBX earnings forecast. How were Unity Biotechnology's earnings last quarter? Unity Biotechnology, Inc. (NASDAQ:UBX) released its quarterly earnings data on Monday, April, 15th. The company reported ($0.53) earnings per share for the quarter. When did Unity Biotechnology's stock split? Shares of Unity Biotechnology reverse split on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Unity Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK). When did Unity Biotechnology IPO? Unity Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager. How do I buy shares of Unity Biotechnology? Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UBX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unity Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
